
Abivax SA (ABVX) Stock Forecast & Price Target
Abivax SA (ABVX) Analyst Ratings
Bulls say
Abivax is a clinical-stage biotechnology company focused primarily on developing a first-in-class modulator of miR-124, obefazimod, for the treatment of inflammatory bowel diseases (IBD). The company's Phase 3 data for obefazimod in ulcerative colitis (UC) showed best-in-disease maintenance efficacy, high rates of endoscopic improvement and remission, and a favorable safety profile. Despite a delay in Phase 2b data for obefazimod in Crohn's disease (CD), the drug's potential efficacy and favorable safety profile, along with a growing patient population in the IBD market, make for a promising outlook on the company's stock.
Bears say
Abivax is facing potential safety concerns with its drug candidate obefazimod due to a higher incidence of malignancies and skin cancer compared to its competitor, Skyrizi. Despite promising efficacy data, the possibility of a black box warning for obefazimod could significantly impact its market share and increase marketing costs. With the potential for regulatory and commercialization delays and competition from emerging therapies, the stock is expected to remain range bound in the near future.
This aggregate rating is based on analysts' research of Abivax SA and is not a guaranteed prediction by Public.com or investment advice.
Abivax SA (ABVX) Analyst Forecast & Price Prediction
Start investing in Abivax SA (ABVX)
Order type
Buy in
Order amount
Est. shares
0 shares